 |
 |
|
|
|
|
||||||||
|
|
|
|
Friday September 10, 2004
Emerging Technologies — Opportunity or Risk? New companies are frequently founded on the basis of bringing emergent technologies to the marketplace, often at the expense of existing market leaders. These start-ups are characterized by a very high failure rate and few will ultimately mature to stable companies with ongoing revenues. In this seminar, Myers examines the growth of new and existing enterprises in regards to emergent new technologies. He discusses strategies that can shift the balance from risk to opportunity and provides examples in the biological sciences, material and information technologies that demonstrate where and under what conditions these disruptive emergent technologies will be found. Other topics include invention and business concept generation, real option reasoning and the interplay of market and technology forces. Mark Myers is a visiting executive professor in the Management Department at the Wharton School. His research interests include identifying emerging markets and technologies to enable growth in new and existing companies with special emphases on technology identification and selection, product development and technology competences. Dr. Myers actively consults on national innovation policy matters. He is the former Sr. Vice President for Xerox corporate research and engineering. Saturday September 25, 2004
Polymers for Biomedical and Opto-electronic Device Applications This presentation looks at polymers and their unique principles that enable new applications in the biomedical industry such as polymeric systems for tissue engineering and controlled drug release. Advanced drug delivery systems are currently a multi-billion dollar industry in the United States alone, and Composto discusses how polymers are being used to control the temporal and spatial distribution of drug molecules in the body. He also examines their application in opto-electronics and the far-out possibility of an all-plastic computer with polymer/organic based conductors, transistors and displays. Russell Composto received his BS in physics from Gettysburg College and his MS and PhD in materials science and engineering from Cornell University, before joining the University of Pennsylvania's School of Engineering and Applied Science (Penn Engineering) in 1990. A member of the American Physical, American Chemical and Materials Science societies, Professor Composto is also the recipient of the National Science Foundation Presidential Young Investigator award. His research areas include tissue engineering, polymer thin films and coatings, nanocomposites, surface engineering via biopolymer adsorption, and surface and interfacial segregation. Friday October 8, 2004
Microfluidics (Lab on a Chip) and Biosensors Technology What exactly are "labs on a chip" or micro total analysis system (mTAS)? How do they differ from their macroscopic counterparts? Bau's lecture addresses various issues related to microfluidics and labs on a chip, such as what and who drives this technology, its current, emerging and future applications and the market outlook for mTAS. Materials and manufacturing techniques, means for propelling and stirring fluids in microfluidic systems, sample processing, and sample analysis and sensing are also discussed. After receiving his BS and MS degrees from Technion in Haifa, Israel, and his PhD in mechanical engineering from Cornell University, Professor Bau joined the University of Pennsylvania in 1980. In 1989, he spent a 6-month sabbatical at the Royal Institute of Technology in Sweden. A fellow of the ASME, a Presidential Young Investigator (1984) and winner of the ASME-Heat Transfer Division Best Paper Award, Professor Bau has authored and co-authored more than 90 archival journal publications and more than 47 proceedings papers. He has co-edited seven books and proceedings volumes and he regularly lectures around the world. Saturday October 23, 2004
New Trends in Drug Discovery The pharmaceutical industry faces great pressures to enhance drug discovery productivity and yet many companies are currently facing empty pipelines. The decline in productivity coincides with increased investment in drug discovery technologies as well as the complete sequencing of the human genome. In this seminar, Diamond looks at current drug development technologies and their limitations and offers a critical evaluation of new trends in the industry's pursuit of new chemical entities. Scott Diamond is a Professor of Chemical Engineering, a Charter Member of the Institute for Medicine and Engineering and Director of the Master of Biotechnology Program at the University of Pennsylvania. He also holds secondary appointments in Bioengineering and Pharmacology. He received his BS from Cornell University and his PhD from Rice University. Dr. Diamond has been a consultant for several biotechnology and pharmaceutical companies and received the 1999 Colburn Award from the American Institute of Chemical Engineers (AIChE). Dr. Diamond has published more than 70 papers and patents. His research interests include non-viral gene transfer, thrombolytic therapy, thrombosis, endothelial mechanobiology, and functional proteomics technologies for phenotyping blood.
|
|
||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||
|
© 2005 University of Pennsylvania. All Rights Reserved. |
|||||||||||||||||||||||||||||||||||||
